Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Geriatric chronic kidney disease patients benefit from SGLT2 inhibition (opens in a new tab)

news-medical.net · 2026-10-26

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. One other point was not covered by the paper.

  • 4 supported
  • 1 overstated
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Four of six check out. One claim the study doesn't address.

  • 4 supported
  • 1 overstated
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedSchmidt also said that even the oldest and most vulnerable CKD patients can derive substantial benefits from SGLT2 inhibitor treatment, but that these medications may not be without risk and require careful, individualized risk-benefit assessment and close clinical monitoring.View evidenceHide evidence

Why this verdict

The caution about risks, individualized risk-benefit assessment, and monitoring is consistent with the reported AKI, AMI, and acute heart failure safety signals. However, the statement that patients 'can derive substantial benefits from SGLT2 inhibitor treatment' presents a stronger treatment-benefit/causal interpretation than the abstract-level retrospective EHR cohort can establish. The paper supports associations with lower mortality and MAKE, not definitive causal benefit.

1

Study evidence

SGLT2i initiation was associated with lower all-cause mortality compared with non-use in propensity-score matched adults ≥80 years with CKD.aHR 0.818 (95% CI 0.746–0.896), p<0.0001

“This retrospective cohort study used data from TriNetX Research Network, a multicenter electronic health record database.”
2

Study evidence

No significant difference in major adverse cardiovascular events (MACE) between SGLT2i initiators and non-initiators.aHR 1.007 (95% CI 0.938–1.082; p=0.84)

“major adverse cardiovascular events (MACE)”
Claim 2 of 6Not coveredThe findings will be presented at ASN Kidney Week 2026 October 22–25.View evidenceHide evidence

Why this verdict

The supplied paper profile does not include conference venue/date metadata verifying presentation at ASN Kidney Week 2026 on October 22–25. This may be true from article or meeting metadata, but it is not verifiable from the abstract-level scientific profile provided.

Claim 3 of 6SupportedNew research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD).View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the study examined both potential benefits and risks of SGLT2 inhibitor initiation in adults aged ≥80 years with CKD. The headline wording is hedged as 'potential' and does not exceed the abstract’s observational association framing.

1

Study evidence

SGLT2i initiation was associated with lower all-cause mortality compared with non-use in propensity-score matched adults ≥80 years with CKD.aHR 0.818 (95% CI 0.746–0.896), p<0.0001

“This retrospective cohort study used data from TriNetX Research Network, a multicenter electronic health record database.”
2

Study evidence

No significant difference in major adverse cardiovascular events (MACE) between SGLT2i initiators and non-initiators.aHR 1.007 (95% CI 0.938–1.082; p=0.84)

“major adverse cardiovascular events (MACE)”
Claim 4 of 6SupportedIn an analysis of electronic health records data on 10,076 adults aged 80 years or older with CKD, initiating SGLT2 inhibitor therapy was linked to an 18% reduction in all-cause mortality and a 22% reduction in major adverse kidney events over a 2-year follow-up.View evidenceHide evidence

As stated18% reduction in all-cause mortality; 22% reduction in major adverse kidney events

Why this verdict

The profile reports 5,038 matched SGLT2i initiators and 5,038 matched non-users, totaling 10,076 adults aged ≥80 years with CKD, using EHR data. It reports all-cause mortality aHR 0.818 and MAKE aHR 0.779 over approximately/up to 2 years, which corresponds closely to relative reductions of about 18% and 22%. The story frames the result associationally as 'linked to,' which matches the observational evidence.

1

Study evidence

SGLT2i initiation was associated with lower all-cause mortality compared with non-use in propensity-score matched adults ≥80 years with CKD.aHR 0.818 (95% CI 0.746–0.896), p<0.0001

“This retrospective cohort study used data from TriNetX Research Network, a multicenter electronic health record database.”
Claim 5 of 6SupportedThe article says there was no significant effect on major adverse cardiovascular events overall, but SGLT2 inhibitors were associated with higher risks of specific cardiac events like heart attacks and acute heart failure, as well as acute kidney injury.View evidenceHide evidence

Why this verdict

The profile reports no significant difference in MACE overall, while acute myocardial infarction, acute heart failure, and acute kidney injury were higher in the SGLT2i group. The story’s wording is associational and consistent with the abstract-level evidence, though the abstract does not provide numerical effect estimates for these safety/component outcomes.

1

Study evidence

No significant difference in major adverse cardiovascular events (MACE) between SGLT2i initiators and non-initiators.aHR 1.007 (95% CI 0.938–1.082; p=0.84)

“major adverse cardiovascular events (MACE)”
Claim 6 of 6SupportedCorresponding author Bernhard M. W. Schmidt said very elderly individuals are historically underrepresented in or systematically excluded from large randomized controlled trials, and that real-world data addresses a blind spot in current medical literature.View evidenceHide evidence

Why this verdict

The underlying scientific content is supported: the profile states that adults aged ≥80 years have been underrepresented in prior large SGLT2 inhibitor trials and that the study used real-world EHR data to evaluate this population. The exact author quotation and attribution are not independently present in the paper profile, but the substance aligns with the abstract-level introduction and objective.

1

Study evidence

SGLT2i initiation was associated with lower all-cause mortality compared with non-use in propensity-score matched adults ≥80 years with CKD.aHR 0.818 (95% CI 0.746–0.896), p<0.0001

“This retrospective cohort study used data from TriNetX Research Network, a multicenter electronic health record database.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Renal component findings: incident dialysis and end-stage renal disease were significantly reduced among SGLT2i initiators.

    The story reflects the composite MAKE reduction but does not mention the profile’s reported reductions in incident dialysis and ESRD.

    From Retrospective EHR cohort with propensity-score matching

  • Subgroup analyses: the abstract says results were generally consistent across subgroups but gives no subgroup-specific estimates or subgroup definitions.

    The story does not discuss subgroup analyses or the limited reporting of those analyses.

    From Subgroup/stratified analyses within propensity-score matched retrospective EHR cohort

6 things the story did carry across
  • Study design: retrospective observational EHR cohort using TriNetX data, not a randomized trial.
  • Population and sample: adults aged ≥80 years with CKD; 5,038 matched SGLT2i initiators and 5,038 matched non-users, totaling 10,076.
  • Primary benefit findings: SGLT2i initiation was associated with lower all-cause mortality and fewer major adverse kidney events over about 2 years.
  • Cardiovascular/safety findings: no significant MACE difference overall, but higher AKI and increased acute myocardial infarction and acute heart failure were reported.
  • Confounding limitation: despite propensity score matching, residual confounding remains possible in the retrospective observational EHR design.
  • Follow-up limitation: outcomes were reported over approximately/up to 2 years, so longer-term durability and safety beyond that period are not established in the abstract.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataAssess whether initiation of SGLT2 inhibitors (vs non-use) is associated with lower all-cause mortality and improved kidney outcomes (MAKE and related renal endpoints) in adults aged ≥80 years with chronic kidney disease using real-world EHR data.Retrospective EHR cohort with propensity-score matchingExpand

In plain English

Retrospective, propensity score–matched cohort study of adults aged ≥80 years with chronic kidney disease in the TriNetX multicenter EHR network (index events 2021-01-01 to 2025-01-01). Among 5,038 matched SGLT2i initiators and 5,038 matched non-users followed for up to two years, initiation of SGLT2 inhibitors was associated with lower all-cause mortality and fewer major adverse kidney events (MAKE) but no difference in major adverse cardiovascular events (MACE). Certain safety signals were reported (higher acute kidney injury, increased acute myocardial infarction and acute heart failure), while incident dialysis and end-stage renal disease were reduced. Analyses used propensity score matching to balance baseline covariates and Cox proportional hazards models to estimate adjusted hazard ratios.

Key findings

  • SGLT2i initiation was associated with lower all-cause mortality compared with non-use in propensity-score matched adults ≥80 years with CKD.aHR 0.818 (95% CI 0.746–0.896), p<0.0001
  • SGLT2i initiation was associated with fewer major adverse kidney events (MAKE).aHR 0.779 (95% CI 0.715–0.850), p<0.0001
“This retrospective cohort study used data from TriNetX Research Network, a multicenter electronic health record database.”
What this piece can’t prove
  • Retrospective observational design using EHR data; despite propensity score matching, residual confounding is possible.

3 further details could not be confirmed from the summary.

2secondary dataAssess whether SGLT2 inhibitor initiation is associated with cardiovascular outcomes (MACE and component cardiac events) and safety signals (e.g., AKI) in the same very-elderly CKD cohort.Retrospective EHR cohort with propensity-score matching and Cox proportional hazards time-to-event analysisExpand

In plain English

In a TriNetX-derived, propensity-score matched retrospective cohort of adults ≥80 years with CKD (5,038 SGLT2i initiators vs 5,038 non-initiators, 2-year follow-up), SGLT2i initiation was not associated with a difference in MACE but was reported to have higher risk of acute kidney injury and increased rates of acute myocardial infarction and acute heart failure (effect estimates for these safety/component events not provided in the abstract).

Key findings

  • No significant difference in major adverse cardiovascular events (MACE) between SGLT2i initiators and non-initiators.aHR 1.007 (95% CI 0.938–1.082; p=0.84)
  • Risk of acute kidney injury (AKI) was reported to be higher in the SGLT2i group.
“major adverse cardiovascular events (MACE)”
What this piece can’t prove
  • Retrospective EHR data are subject to residual confounding and potential misclassification despite propensity-score matching.
  • Multiplicity of tested outcomes and subgroup analyses not detailed; potential for type I error in reporting increased component events.

1 further detail could not be confirmed from the summary.

3secondary dataEvaluate whether observed associations are consistent across prespecified/clinically relevant subgroups within the matched cohort.Subgroup/stratified analyses within propensity-score matched retrospective EHR cohortExpand

In plain English

The abstract reports that subgroup/stratified analyses were performed within the propensity-score matched TriNetX cohort and that overall results were "generally consistent across subgroups." The abstract provides no subgroup-specific effect estimates, confidence intervals, list of subgroups, or information about prespecification or multiple-comparison adjustment.

Key findings

  • "Results were generally consistent across subgroups." (abstract statement; no subgroup-specific estimates reported)
“Results were generally consistent across subgroups.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

WCN25-4094 INTACT FIBROBLAST GROWTH FACTOR 23 AND MAJOR ADVERSE KIDNEY EVENTS IN CHRONIC KIDNEY DISEASE

Kidney International Reports · 2025 · Crossref

Source (opens in a new tab)
Candidate

Review for "Risk acceleration by gout on major adverse cardiovascular events and all‐cause death in patients with diabetes and chronic kidney disease"

2024 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.